

## LETTER to the EDITOR

**In Regard to Wang et al on Long-term Outcomes Following D2 Gastrectomy for Early Gastric Cancer***Asian Pac J Cancer Prev*, 16 (7), 3083**Dear Editor**

I read with great interest the long-term outcomes following D2 gastrectomy for early gastric cancer (EGC) reported by Zheng Wang and colleagues (Wang et al., 2014). I would like to congratulate the authors for their excellent efforts in reviewing a large number of patient records treated over a period spanning more than 14 years. Findings from this study further confirmed the good prognosis of the overall patient population with EGC following treatment.

However, it would be interesting to learn more about the use of adjuvant treatment, pattern of treatment failures, rate of *Helicobacter pylori* positivity and effect of *H. pylori* eradication in this study population. The role of adjuvant therapy for patients who have undergone complete resection of EGC is not clearly established (NCCN, 2014). There is no consensus as to the best approach. Practice varies widely, depending mainly on geographical location. More data on use of adjuvant treatment following resection of EGC and pattern of treatment failures would help to shed some light on the effects on long-term outcomes, while results from randomized controlled trials are eagerly awaited.

*H. pylori* is a well-defined risk factor for EGC. Despite being widely practised, the exact benefits of *H. pylori* eradication continue to be debated, and the survival advantage remains unclear (Wong et al., 2004; Freedberg et al., 2014; Kwon et al., 2014; Li et al., 2014). I urge the authors to publish data on *H. pylori* rate and analyse the effect of *H. pylori* positivity and its eradication on incidence of metachronous disease and survival.

Nevertheless, the excellent survival reported in this single institution study from a developing country without a dedicated screening programme is commendable and comparable to published literature from elsewhere (Okada et al., 2012).

**References**

- Freedberg DE, Abrams JA, Wang TC (2014). Prevention of gastric cancer with antibiotics: can it be done without eradicating *Helicobacter pylori*? *J Natl Cancer Inst*, **106**, 148.
- Kwon YH, Heo J, Lee HS, Cho CM, Jeon SW (2014). Failure of *Helicobacter pylori* eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. *Alimentary Pharmacology Therapeutics*, **39**, 609-18.

Li WQ, Ma JL, Zhang L, et al (2014). Effects of *Helicobacter pylori* treatment on gastric cancer incidence and mortality in subgroups. *J Natl Cancer Inst*, **106**, 116.

NCCN Clinical Practice Guideline on Gastric Cancer v1.2014. [http://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf) (Accessed on October 12, 2014).

Okada K, Fujisaki J, Yoshida T, et al (2012). Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. *Endoscopy*, **44**, 122-7.

Wang Z, Ma L, Zhang XM, Zhou ZX (2014). Long-term outcomes after D2 gastrectomy for early gastric cancer: survival analysis of a single-center experience in China. *Asian Pac J Cancer Prev*, **15**, 7219-7222.

Wong BCY, Lam SK, Wong WM, et al (2004). *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA*, **291**,

**Weng Heng Tang**

*Clinical Oncology, Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia* \*For correspondence: [tangwengheng@ummc.edu.my](mailto:tangwengheng@ummc.edu.my)